Cargando…

EGFR exon 19 deletion switch and development of p.L792Q mutation as a new resistance mechanism to osimertinib: a case report and literature review

Epidermal growth factor receptor (EGFR) gene mutations play an important role in the treatment management of non-small cell lung cancer (NSCLC) patients. After a first- or second-generation EGFR tyrosine kinase inhibitor (TKI) therapy, the most common resistance mechanism involves the selection of a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pisapia, Pasquale, Rocco, Danilo, Pepe, Francesco, De Luca, Caterina, Battiloro, Ciro, Smeraglio, Riccardo, Cieri, Miriam, Bellevicine, Claudio, Troncone, Giancarlo, Malapelle, Umberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798167/ https://www.ncbi.nlm.nih.gov/pubmed/35117065 http://dx.doi.org/10.21037/tcr.2018.09.13

Ejemplares similares

A strategy to overcome EGFR p.T790M cis p.L792F induced resistance to osimertinib
por: Malapelle, Umberto, et al.
Publicado: (2022)

Next-Generation Sequencing of Lung Cancer EGFR Exons 18-21 Allows Effective Molecular Diagnosis of Small Routine Samples (Cytology and Biopsy)
por: de Biase, Dario, et al.
Publicado: (2013)

KRAS detection on archival cytological smears by the novel fully automated polymerase chain reaction-based Idylla mutation test
por: De Luca, Caterina, et al.
Publicado: (2017)

Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases
por: Malapelle, Umberto, et al.
Publicado: (2016)

Next generation sequencing in cytology
por: Pisapia, Pasquale, et al.
Publicado: (2021)

Cytology in the time of coronavirus disease (COVID-19): an Italian perspective
por: Vigliar, Elena, et al.
Publicado: (2021)

BRCA1/2 NGS Somatic Testing in Clinical Practice: A Short Report
por: Pepe, Francesco, et al.
Publicado: (2021)

Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma
por: Peng, MuYun, et al.
Publicado: (2020)

Understanding EGFR heterogeneity in lung cancer
por: Passaro, Antonio, et al.
Publicado: (2020)

A narrative review of lung cancer cytology in the times of coronavirus: what physicians should know
por: Pisapia, Pasquale, et al.
Publicado: (2020)

Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort
por: Fairclough, Stephen R., et al.
Publicado: (2019)

KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting
por: Nacchio, Mariantonia, et al.
Publicado: (2020)

Second-line avelumab in platinum-treated non-small cell lung cancer patients: comment on the JAVELIN Lung 200 clinical trial
por: Rocco, Danilo, et al.
Publicado: (2019)

Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR
por: Della Corte, Carminia Maria, et al.
Publicado: (2017)

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
por: Murano, Chihiro, et al.
Publicado: (2019)

Correction: Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR
por: Corte, Carminia Maria Della, et al.
Publicado: (2022)

BRAF: A Two-Faced Janus
por: Pisapia, Pasquale, et al.
Publicado: (2020)

Liquid Biopsy in Prostate Cancer Management—Current Challenges and Future Perspectives
por: Crocetto, Felice, et al.
Publicado: (2022)

KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy
por: Bruera, Gemma, et al.
Publicado: (2018)

Blockade of STAT3/IL-4 overcomes EGFR T790M-cis-L792F-induced resistance to osimertinib via suppressing M2 macrophages polarization
por: Sun, Yiting, et al.
Publicado: (2022)

Biomarkers predictive value in early stage non-small cell lung cancer
por: Malapelle, Umberto, et al.
Publicado: (2020)

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
por: Fang, Wenfeng, et al.
Publicado: (2019)

Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC
por: Cekay, Michael, et al.
Publicado: (2023)

Thyroid fine-needle aspiration trends before, during, and after the lockdown: what we have learned so far from the COVID-19 pandemic
por: Palladino, Raffaele, et al.
Publicado: (2020)

Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients
por: Malapelle, Umberto, et al.
Publicado: (2017)

PD‐L1 and beyond: Immuno‐oncology in cytopathology
por: Iaccarino, Antonino, et al.
Publicado: (2021)

Harmonization of Next-Generation Sequencing Procedure in Italian Laboratories: A Multi-Institutional Evaluation of the SiRe® Panel
por: Malapelle, Umberto, et al.
Publicado: (2020)

Poor effect of osimertinib on EGFR exon 20 insertion-positive lung adenocarcinoma: A case report
por: Inagaki, Yuji, et al.
Publicado: (2020)

Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence
por: Attili, Ilaria, et al.
Publicado: (2022)

L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatment
por: Li, Meihui, et al.
Publicado: (2022)

A Diode Matrix model M792
Publicado: (2017)

MicroRNA Signature of Lung Adenocarcinoma with EGFR Exon 19 Deletion
por: Ju, Lixia, et al.
Publicado: (2017)

Next Generation Sequencing in Cytopathology: Focus on Non-Small Cell Lung Cancer
por: Pisapia, Pasquale, et al.
Publicado: (2021)

Immunotherapy as a targeted therapy in non-small cell lung cancer
por: Rocco, Danilo, et al.
Publicado: (2019)

Evaluation of Micro Satellite Instability and Mismatch Repair Status in Different Solid Tumors: A Multicenter Analysis in a Real World Setting
por: Malapelle, Umberto, et al.
Publicado: (2021)

Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer
por: Zhao, Shen, et al.
Publicado: (2023)

Activity of osimertinib in a patient with stage IV non-small cell lung cancer harboring HER2 exon 19, p.L755P mutation: case report
por: Jonsdottir, Gudbjorg, et al.
Publicado: (2023)

Distal‐type bronchiolar adenoma of the lung harboring an EGFR exon 21 p.L858R mutation: A case report
por: Yang, Chenglin, et al.
Publicado: (2020)

An Italian Multicenter Perspective Harmonization Trial for the Assessment of MET Exon 14 Skipping Mutations in Standard Reference Samples
por: Bironzo, Paolo, et al.
Publicado: (2023)

Interventional cytopathologist can successfully combine ultrasonographical and microscopic skills to narrow the differential diagnosis in fine needle aspiration of neck paraganglioma
por: Carillo, Anna Maria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0t7c1uk5b6opfdiv0sj1b3ilcj